SCHEMBL732892

SCHEMBL732892

COC(=O)CCC(CCC(=O)OC)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.57
SLC1A1 P43005 1/20 0.46
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 3/20 0.41
CA12 O43570 3/20 0.41
CA14 Q9ULX7 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9602990 0.91 TSHR (0.48) TSHRSLC1A1KMT2AMEN1LMNA
SCHEMBL9602992 0.91 TSHR (0.48) TSHRSLC1A1KMT2AMEN1LMNA
SCHEMBL28360019 0.89 TSHR (0.50) TSHRSLC1A1KMT2AMEN1LMNA
SCHEMBL17526790 0.88 TSHR (0.46) TSHRSLC1A1CA12CA14CA7
SCHEMBL17526664 0.88 TSHR (0.46) TSHRSLC1A1CA12CA14CA7
SCHEMBL14066245 0.85 TSHR (0.46) TSHRSLC1A1KMT2AMEN1LMNA
SCHEMBL17524012 0.84 TSHR (0.43) TSHRSLC1A1KMT2AMEN1LMNA
SCHEMBL17524011 0.84 TSHR (0.43) TSHRSLC1A1KMT2AMEN1LMNA
SCHEMBL29227996 0.82 TSHR (0.56) TSHRKMT2ALMNAALDH1A1L3MBTL1
SCHEMBL9516151 0.82 TSHR (0.43) TSHRSLC1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 US disclosed
US-20240150756-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-05-09 US disclosed
US-20240117347-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-04-11 US disclosed
EP-4344744-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-04-03 EP disclosed
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
EP-4219516-A2 CHIRAL CONTROL Wave Life Sciences Ltd. (SG) 2023-08-02 EP disclosed
US-11643657-B2 Chiral control WAVE LIFE SCIENCES LTD. (SG) 2023-05-09 US disclosed
US-11634710-B2 Oligonucleotide compositions and methods thereof WAVE LIFE SCIENCES LTD. (SG) 2023-04-25 US disclosed
US-20230089442-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-03-23 US disclosed
US-11608355-B2 Technologies for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2023-03-21 US disclosed
US-8138330-B2 Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite SIGMA-ALDRICH CO. LLC (US) 2012-03-20 US disclosed
US-20110294124-A1 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS WAVE LIFE SCIENCES LTD. (SG) 2011-12-01 US disclosed
EP-2370451-A2 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS Chiralgen, Ltd. (JP) 2011-10-05 EP disclosed
WO-2011005761-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF ONTORII, INC (US) 2011-01-13 WO disclosed
WO-2010064146-A2 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS CHIRALGEN, LTD. (JP) 2010-06-10 WO disclosed
US-20080064867-A1 PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES SIGMA ALDRICH COMPANY (US) 2008-03-13 US disclosed
US-5808035-A OLIGOMER BIOSYNTHESIS USHER, DAVID A. 1998-09-15 US disclosed
US-5623068-A Synthesis of DNA using substituted phenylacetyl-protected nucleotides BECKMAN INSTRUMENTS, INC. (US) 1997-04-22 US disclosed
EP-0749436-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1996-12-27 EP disclosed
WO-1995024413-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1995-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150756-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RBM17, HNRNPA2B1, HNRNPA1 TSHR 3181/4885SLC1A1 1352/4885KMT2A 1986/4885
US-20080064867-A1 PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES RNGTT, DUT, ADAR TSHR 2956/4885SLC1A1 3834/4885KMT2A 1866/4885
US-11608355-B2 Technologies for oligonucleotide preparation POLRMT, DCLRE1B, RNGTT TSHR 2860/4885SLC1A1 4680/4885KMT2A 1707/4885
US-20240229026-A1 CHIRAL CONTROL RNGTT, POLI, NSUN3 TSHR 3259/4885SLC1A1 3161/4885KMT2A 2211/4885
US-20110294124-A1 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS PNP, ADAR, NUDT1 TSHR 2664/4885SLC1A1 3449/4885KMT2A 2183/4885
US-20240117347-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RBM17, HNRNPA2B1, HNRNPA1 TSHR 3181/4885SLC1A1 1352/4885KMT2A 1986/4885
US-20230089442-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, POLM TSHR 3108/4885SLC1A1 4353/4885KMT2A 2105/4885
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT TSHR 2860/4885SLC1A1 4680/4885KMT2A 1707/4885
US-11643657-B2 Chiral control RNGTT, POLI, NSUN3 TSHR 3259/4885SLC1A1 3161/4885KMT2A 2211/4885
US-11634710-B2 Oligonucleotide compositions and methods thereof RBM17, HNRNPA2B1, HNRNPA1 TSHR 3181/4885SLC1A1 1352/4885KMT2A 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.